Skip Navigation

This Article
Right arrow Abstract Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Disclaimer
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Alpert, J.S.
Right arrow Articles by Henry, T.D.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Alpert, J.S.
Right arrow Articles by Henry, T.D.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


Issues in antithrombin therapy for UA/NSTEMI

J.S. Alpert*,1, A.J. Budaj2, E.P. Gurfinkel3 and T.D. Henry4

1 University of Arizona College of Medicine, Tucson, Arizona, USA
2 Postgraduate Medical School, Warsaw, Poland
3 Favoloro Foundation, Buenos Aires, Argentina
4 Hennepin County Medical Center, Minneapolis, Minnesota, USA

* Correspondence: Joseph S. Alpert, University of Arizona College of Medicine, Tucson, Arizona, USA

Abstract

In September 2000, participants at the 4th Annual Experts' Meeting of the International Cardiology Forum convened to discuss guidelines for the management of unstable angina/non-ST-elevation MI, recently published by North American and European task forces. Discussion of new recommendations for antithrombin therapy focused on the role of low-molecular-weight heparin (LMWH). Although most participants found the new guidelines largely consistent with existing data, and sufficiently adaptable to most clinical settings, there was concern that neither task force specified LMWH as the antithrombin of choice for the medical management of these patients. The new guidelines continue to endorse the use of unfractionated heparin, particularly for high-risk patients, despite the evidence for the efficacy of LMWH in this setting. This is largely a consequence of the dominant role assigned to the GP IIb/IIIa inhibitors and to an early interventional strategy. It was generally agreed that more data on the use of LMWH in combination with GP IIb/IIIa antagonists would be helpful, as well as more information to guide the transition from medical management to the cath lab. The optimal duration of antithrombin therapy was also the subject of discussion, particularly for patients unable to undergo immediate revascularization.

Key Words: Unstable angina • antithrombin • heparin • low-molecular-weight heparin • guidelines

References

  1. Braunwald E, Brown J, Brown L, et al. Unstable angina: diagnosis and management. Clinical practice guideline number 10. AHCPR Publication No. 94–0602. Rockville: US Department of Health and Human Services, Agency for Health Care Policy and Research and the National Heart, Lung, and Blood Institute; 1994.
  2. Klein W, Buchwald A, Hillis SE, et al. Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease. Circulation. 1997;:61–68
  3. The FRAX.I.S Study Group. Comparison of two treatment durations (6 days and 14 days) of a low molecular weight heparin with a 6-day treatment of unfractionated heparin in the initial management of unstable angina or non-Q wave myocardial infarction: FRAX.I.S, FRAXiparine in Ischaemic Syndrome. Eur Heart J. 1999;20:1553–1562[Abstract/Free Full Text]
  4. Cohen M, Demers C, Gurfinkel E, et al. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. N Engl J Med. 1997;337:447–452[Abstract/Free Full Text]
  5. Antman EM, McCabe CH, Gurfinkel EP, et al. Enoxaparin prevents death and cardiac ischaemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial. Circulation. 1999;100:1593–1601[Abstract/Free Full Text]
  6. Antman EM, Fox KM. Guidelines for the diagnosis and management of unstable angina and non-Q-wave myocardial infarction: proposed revisions. The International Cardiology Forum. Am Heart J. 2000;139:461–475[CrossRef][Web of Science][Medline]
  7. Bertrand ME, Simoons ML, Fox KAA, et al. Management of acute coronary syndromes: acute coronary syndromes without persistent ST segment elevation; recommendations of the Task Force of the European Society of Cardiology. (chair)Eur Heart J. 2000;21:1406–1432[Free Full Text]
  8. Braunwald E, Antman EM, Beasley JW, et al. ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction: executive summary and recommendations: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Patients With Unstable Angina). J Am Coll Cardiol. 2000;36:970–1062[Free Full Text]
  9. Braunwald E, Antman EM, Beasley JW, et al. ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction: executive summary and recommendations: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Patients With Unstable Angina). Circulation. 2000;102:1193–1209[Free Full Text]
  10. Fragmin and Fast Revascularisation during Instability in Coronary artery disease Investigators. Long-term low-molecular-mass heparin in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. Lancet. 1999;354:701–707[CrossRef][Web of Science][Medline]
  11. Organisation to Assess Strategies for Ischemic Syndromes (OASIS-2) Investigators. Effects of recombinant hirudin (lepirudin) compared with heparin on death, myocardial infarction, refractory angina, and revascularisation procedures in patients with acute myocardial ischaemia without ST elevation: a randomised trial. Lancet. 1999;353:429–438[CrossRef][Web of Science][Medline]
  12. Mehta S, Yusuf S, Rupprecht J-J, et al. Substantial benefit of hirudin compared to heparin among unstable angina patients undergoing early percutaneous coronary intervention. Organisation to Assess Strategies for Ischemic Syndromes (OASIS-2) Investigators. J Am Coll Cardiol. 2000;353:357A
  13. Rev Urug Cardiol. 1998;13:127–140
  14. Gurfinkel E. Current treatment and future prospects for the management of acute coronary syndromes. Tierra del Fuego, ArgentinaN Cn Drug Invest. 1998. p. 367–380
  15. Morrow DA, Antman EM, Tanasijevic M, et al. Cardiac troponin I for stratification of early outcomes and the efficacy of enoxaparin in unstable angina: a TIMI-11B substudy. J Am Coll Cardiol. 2000;36:1812–1817[Abstract/Free Full Text]
  16. Boersma E, Akkerhuis KM, Théroux P, et al. Platelet glycoprotein IIb/IIIa receptor inhibition in non-ST-elevation acute coronary syndromes: early benefit during medical treat ment only, with additional protection during percutaneous coronary intervention. Circulation. 1999;100:2045–2048[Abstract/Free Full Text]
  17. The PURSUIT Trial Investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. Platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrilin therapy. N Engl J Med. 1998;339:436–443[Abstract/Free Full Text]
  18. The PRISM-PLUS Investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. N Engl J Med. 1998;338:1488–1497[Abstract/Free Full Text]
  19. The CAPTURE Investigators. Randomised placebocontrolled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE study. Lancet. 1997;349:1429–1435[CrossRef][Web of Science][Medline]
  20. Hamm C, Heeschen C, Goldman B, et al. Benefit of abciximab in patients with refractory unstable angina in relation to serum troponin level. N Engl J Med. 1999;340:1623–1629[Abstract/Free Full Text]
  21. Heeschen C, Hamm C, Goldmann B, Deu A, Langenbrink L, White L. Troponin concentrations for stratification of patients with acute syndromes in relation to therapeutic efficacy of tirofiban. Lancet. 1999;354:1757–1762[CrossRef][Web of Science][Medline]
  22. Goodman SG, Cohen M, Bigonzi F, et al. Randomized trial of low molecular weight heparin (enoxaparin) versus unfractionated heparin for unstable coronary artery disease: one-year results of the ESSENCE Study: Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q Wave Coronary Events. J Am Coll Cardiol. 2000;36:693–698[Abstract/Free Full Text]
  23. Collignon F, Frydman A, Captain H et al. Comparison of the pharmacokinetic profiles of three low molecular mass heparins — dalteparin, enoxaparin and nadroparin — administered subcutaneously in healthy volunteers (doses for prevention of thromboembolism), Thromb Haemost; 73: 630–640.
  24. Granger CB, Hirsh J, Califf RM, et al. Activated partial thromboplastin time and outcome after thrombolytic therapy for acute myocardial infarction: results from the GUSTO-1 trial. Circulation. 1996;93:870–878[Abstract/Free Full Text]
  25. Montalescot G, Cohen M. Low molecular weight heparins in the cardiac catheterization laboratory. J Thromb Thrombolysis. 1999;7:319–323[CrossRef][Web of Science][Medline]
  26. Mark DB, Cowper PA, Berkowitz SD, et al. Economic assessment of low-molecular weight heparin (enoxaparin) versus unfractionated heparin in acute coronary syndrome patients. Circulation. 1998;97:1702–1707[Abstract/Free Full Text]
  27. Fox KAA, Bosanquet N. Assessing the UK cost implications of the use of low molecular weight heparin in unstable coronary artery disease. Br J Cardiol. 1998;5:92–105
  28. Goodman SG, Cohen M, Bigonzi F, et al. Randomized trial of low molecular weight heparin (enoxaparin) versus unfractionated heparin for unstable coronary artery disease: one-year results of the ESSENCE Study: Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q Wave Coronary Events. J Am Coll Cardiol. 2000;36:693–698
  29. Antman EM, Cohen M, Radley D, et al. Assessment of the treatment effect of enoxaparin for unstable angina/ non-Q-wave myocardial infarction: TIMI 11B-ESSENCE Meta-analysis. Circulation. 1999;99:1602–1608
  30. Simoons ML. GUSTO IV ACS (Global Utilisation of Streptokinase and t-PA for Occluded coronary arteries trial IV in Acute Coronary Syndromes): outcome of 7600 patients with acute coronary syndromes randomised to placebo or abciximab for 1 or 2 days. Presented at the 22nd Congress of the European Society of Cardiology. The Netherlands: Amsterdam; August 2000.
  31. Wallentin LC. GUSTO 1V ACS (Global Utilisation of Streptokinase and t-PA for Occluded coronary arteries trial IV in Acute Coronary Syndromes): substudy comparing out comes for the combination of abciximab with standard unfractionated heparin or low molecular weight heparin. Presented at the 22nd Congress of the European Society of Cardiology. The Netherlands: Amsterdam; August 2000.
  32. Young JJ, Kereiakes DJ, Grines CL. Low-molecular-weight heparin therapy in percutaneous coronary intervention: the NICE-1 and NICE-4 trials. National Investigators Collaborating on Enoxaparin (NICE) Investigators. J Invas Cardiol. 2000;12(Suppl E):E14–E18
  33. Ferguson JJ, Antman E, Bates E, et al. The use of enoxaparin and IIb/IIIa antagonists in acute coronary syndromes, including PCI: the NICE-3 study. Washington, DC, USAPresented at Trans catheter Cardiovascular Therapeutics 2000. October 2000.
  34. Kereiakes DJ, Fry E, Lengerich R, et al. Abciximab-associated thrombocytopenia is reduced by enoxaparin: preliminary results of the NICE 4 trial. Barcelona, SpainPresented at the 21st Congress of the European Society of Cardiology. August 1999.
  35. Brouwer M. APRICOT-2 (Antithrombotics in the Prevention of Reocclusion in Coronary Thrombolysis). Presented at the 22nd Congress of the European Society of Cardiology. The Netherlands: Amsterdam; September 2000.
  36. The Organization to Assess Strategies for Ischemic Syndromes (OASIS) Investigators. Effects of long-term, moderate-intensity oral anticoagulation in addition to aspirin in unstable angina. J Am Coll Cardiol. 2001;37:475–484[Abstract/Free Full Text]

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?



This Article
Right arrow Abstract Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Disclaimer
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Alpert, J.S.
Right arrow Articles by Henry, T.D.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Alpert, J.S.
Right arrow Articles by Henry, T.D.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?